DPD Genotyping For Fluorouracil Toxicity

  • Print
  • Email

The Life-Daan DPD Genotyping For Fluorouracil Toxicity is an sequencing base assay for determining the genotype(s) of DPD.

We are sequencing four whole DPD exon regions, exon 2, 13, 14 and 18 mutations for detecting DPD deficiency in chemotherapy cancer patients. This blood test that enables physicians to customize chemotherapy and take action to minimize side effects.


To assess the possibility of severe toxic reactions to 5-FU treatment

【FDA Guidance】 

Capecitabine is a pro-drug of 5-fluorouracil used for the treatment of various types of neoplasms including colorectal and breast neoplasms. Variants in the DPD gene (also known as dihydropyrimidine dehydrogenase and DPD) are associated with increased risk for adverse and potentially toxic events, and therefore Capecitabine (Xeloda) is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency (though genetic testing or screening of DPD activity is not mentioned in the drug label).


  • Low–input DNA protocol (20 ng), compatible with serum/plasma samples
  • Technology: Sanger Sequencing
  • Test results for research use only, cannot be taken as the basis of clinical diagnosis.

【How It Works】

  • Amplification of relevant portions of the DPD coding exon, exon 2, 13, 14 and 18;
  • Gene sequencing with 3500Dx and 3500Dx XL Genetic Analyzer of purified products;
  • Computer analysis to determine mutation presence or absence.

【Applicable population】

  • Patient who will receive 5-Fu, or who has a history of irinotecan sensitivity.
  • Patient who experiences serious side-effect while receiving 5-Fu based drugs.